Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Medtronic
Cantor Fitzgerald
Colorcon
UBS
Federal Trade Commission
Citi
Harvard Business School
QuintilesIMS

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,780,454

« Back to Dashboard

Which drugs does patent 5,780,454 protect, and when does it expire?


Patent 5,780,454 protects VELCADE and is included in one NDA. There has been one Paragraph IV challenge on Velcade.

Protection for VELCADE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-seven patent family members in twenty-five countries.

Summary for Patent: 5,780,454

Title: Boronic ester and acid compounds
Abstract:Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
Inventor(s): Adams; Julian (Brookline, MA), Ma; Yu-Ting (Needham, MA), Stein; Ross (Sudbury, MA), Baevsky; Matthew (Jamaica Plains, MA), Grenier; Louis (Belmont, MA), Plamondon; Louis (Belmont, MA)
Assignee: ProScript, Inc. (Cambridge, MA)
Application Number:08/549,318
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,780,454

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,548,668 Boronic ester and acid compounds, synthesis and uses► Subscribe
6,066,730 Boronic ester and acid compounds, synthesis and uses► Subscribe
7,119,080Boronic ester and acid compounds, synthesis and uses► Subscribe
7,531,526Boronic ester and acid compounds, synthesis and uses► Subscribe
6,297,217 Boronic ester and acid compounds, synthesis and uses► Subscribe
6,465,433 Boronic ester and acid compounds, synthesis and uses► Subscribe
6,617,317 Boronic ester and acid compositions► Subscribe
6,083,903 Boronic ester and acid compounds, synthesis and uses► Subscribe
6,747,150 Boronic ester and acid compounds, synthesis and uses► Subscribe
8,378,099Boronic ester and acid compounds, synthesis and uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,780,454

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany69530936► Subscribe
Finland120974► Subscribe
Hong Kong1002059► Subscribe
Finland20041415► Subscribe
Finland114801► Subscribe
Finland971746► Subscribe
Spain2314540► Subscribe
Spain2254803► Subscribe
European Patent Office1997823► Subscribe
European Patent Office1627880► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Mallinckrodt
QuintilesIMS
Express Scripts
Cerilliant
Merck
US Department of Justice
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot